Journal of Clinical and Cellular Immunology

Journal of Clinical and Cellular Immunology
Open Access

ISSN: 2155-9899

Yongzhao Shao

Division of Biostatistics, Department of Population Health, NYU Grossman School of Medicine, New York University, New York, NY 10016, USA

  • Review Article   
    Hydroxychloroquine and Interferons for the Prophylaxis and Early Treatment of Covid-19-Current Clinical Advances
    Author(s): Alexander Chuan Yang, Youcheng Liu, Yongzhao Shao, Charlotte Zhong Yang, Jinping Xu* and Bing Yang*

    Coronavirus disease 2019 (Covid-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) calls for unprecedented measures to control the spread of the virus. SARS-CoV-2 enters into the cell by direct fusion to the cell membrane or fusion to the membrane of endocytic vesicles. Hydroxychloroquine (HCQ) inhibits enzymes in the endocytic vesicle and has been studied for its efficacy since the beginning of the pandemic. Retrospective analysis of healthcare workers (HCWs) and observational studies suggest protective effect of taking HCQ prophylactically. However, studies on autoimmune patients taking HCQ provide conflicting results. In a postexposure prophylaxis randomized controlled trial (RCT), Boulware et al. found a non-significant difference in incidence between HCQ and placebo group (11.8% vs. 14.3%, p=0.35). However, our re-analysis of.. Read More»
    DOI: 10.35248/2155-9899.20.11.596

    Abstract HTML PDF